Lupin Receives U.S. FDA Approval for Generic Pitolisant Tablets

MUMBAI, India — Indian pharmaceutical multinational Lupin Limited announced on August 17, 2026, that it has received final approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets in 4.45 mg and 17.8 mg dosage strengths. The regulatory milestone establishes full bioequivalence between Lupin's generic formulation and the reference listed drug, Wakix®, expanding treatment options within the United States prescription drug market.

FDA Regulatory Approval and Product Details

The United States Food and Drug Administration granted final approval for Lupin’s Abbreviated New Drug Application (ANDA) following comprehensive technical and bioequivalence evaluations. The generic Pitolisant Tablets, produced in 4.45 mg and 17.8 mg dosages, are therapeutic equivalents to reference listed drug Wakix®, a registered trademark of Bioprojet Europe, Ltd.

The approval grants Lupin authorization to market and distribute the generic formulation across healthcare channels in the U.S. Pitolisant is a selective histamine H3 receptor antagonist/inverse agonist indicated for central nervous system disorders, primarily utilized to manage excessive daytime sleepiness and cataplexy in adult patients.

Strategic Market Impact and Operations

The clearance represents a significant addition to Lupin's ongoing expansion within the American generic and specialty pharmaceutical space. Headquartered in Mumbai, Lupin maintains 15 global manufacturing plants and 6 research facilities, supported by over 26,000 employees.

The introduction of generic pitolisant tablets provides healthcare providers and patients in the United States with an additional accessible therapeutic choice. The approval is expected to heighten market competition for the reference drug Wakix®, potentially offering cost-efficiency benefits to pharmacy benefit managers, healthcare insurers, and consumers.

Official Sources Section

The information detailed in this article reflects the official regulatory disclosure submitted by Lupin Limited under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Formal notices were served directly to the National Stock Exchange of India Limited and the BSE Limited on August 17, 2026.

Quote Section

According to official company announcements released to financial exchanges, "Lupin Limited has received the final approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Pitolisant Tablets, 4.45 mg and 17.8 mg".

Why It Matters

The regulatory clearance enables Lupin to deepen its operational footprint across central nervous system therapies in North America. For United States patients and healthcare professionals, generic availability increases market access and choices for essential prescription medications. Investors and financial analysts view U.S. FDA approvals as critical catalysts for sustaining generic pharmaceutical revenue streams and global market valuation.

Key Facts at a Glance

• Regulatory Body: United States Food and Drug Administration (U.S. FDA).

• Company: Lupin Limited (NSE: LUPIN, BSE: 500257).

• Product Approved: Pitolisant Tablets (4.45 mg and 17.8 mg).

• Reference Drug: Bioequivalent to Wakix®.

• Filing Date: Formal disclosures published August 17, 2026.

Frequently Asked Questions

What approval did Lupin Limited receive from the U.S. FDA?

Lupin Limited received final approval for its Abbreviated New Drug Application (ANDA) for generic Pitolisant Tablets in 4.45 mg and 17.8 mg strengths.

Which brand-name drug is generic Pitolisant equivalent to?

The approved generic Pitolisant Tablets are bioequivalent to Wakix®, which is owned by Bioprojet Europe, Ltd.

When was the approval announced to public stock exchanges?

Lupin officially announced the U.S. FDA approval to the BSE Limited and National Stock Exchange of India Limited on August 17, 2026.

Where is Lupin Limited headquartered?

Lupin Limited is a global pharmaceutical company based in Mumbai, Maharashtra, India.

Source: Lupin Limited Corporate Disclosure to Stock Exchanges, National Stock Exchange of India Limited, BSE Limited.